 | • レポートコード：MRC2-11QY11356 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は脊索腫疾患治療薬のグローバル市場について調査・分析したレポートです。種類別（代謝拮抗剤、アントラサイクリン、VEGFR阻害剤、EGFR阻害剤、その他）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別脊索腫疾患治療薬の競争状況、市場シェア ・世界の脊索腫疾患治療薬市場：種類別市場規模 2015年-2020年（代謝拮抗剤、アントラサイクリン、VEGFR阻害剤、EGFR阻害剤、その他） ・世界の脊索腫疾患治療薬市場：種類別市場規模予測 2021年-2026年（代謝拮抗剤、アントラサイクリン、VEGFR阻害剤、EGFR阻害剤、その他） ・世界の脊索腫疾患治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、その他） ・世界の脊索腫疾患治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、その他） ・北米の脊索腫疾患治療薬市場分析：米国、カナダ ・ヨーロッパの脊索腫疾患治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの脊索腫疾患治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の脊索腫疾患治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの脊索腫疾患治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GlaxoSmithKline、Bavarian Nordic、Boehringer Ingelheim International、Pfizer、Merck、Sanofi、Astellas Pharma、AstraZeneca、Amgen、Bristol-Myers Squibb and Company、Novartis、Bayer、Dr. Reddy’s Laboratories、Mylan ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Chordoma Disease Therapeutics Market
The global Chordoma Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chordoma Disease Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chordoma Disease Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chordoma Disease Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chordoma Disease Therapeutics market.
Global Chordoma Disease Therapeutics Scope and Market Size
Chordoma Disease Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chordoma Disease Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Antimetabolites
Anthracycline
VEGFR Inhibitor
EGFR Inhibitor
Others
Market segment by Application, split into
Hospital
Clinic
Others
Based on regional and country-level analysis, the Chordoma Disease Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Chordoma Disease Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
GlaxoSmithKline
Bavarian Nordic
Boehringer Ingelheim International
Pfizer
Merck
Sanofi
Astellas Pharma
AstraZeneca
Amgen
Bristol-Myers Squibb and Company
Novartis
Bayer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chordoma Disease Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Antimetabolites
1.2.3 Anthracycline
1.2.4 VEGFR Inhibitor
1.2.5 EGFR Inhibitor
1.2.6 Others
1.3 Market by Application
1.3.1 Global Chordoma Disease Therapeutics Market Share by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chordoma Disease Therapeutics Market Perspective (2015-2026)
2.2 Global Chordoma Disease Therapeutics Growth Trends by Regions
2.2.1 Chordoma Disease Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chordoma Disease Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Chordoma Disease Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chordoma Disease Therapeutics Players by Market Size
3.1.1 Global Top Chordoma Disease Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Chordoma Disease Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Chordoma Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chordoma Disease Therapeutics Revenue
3.4 Global Chordoma Disease Therapeutics Market Concentration Ratio
3.4.1 Global Chordoma Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chordoma Disease Therapeutics Revenue in 2019
3.5 Key Players Chordoma Disease Therapeutics Area Served
3.6 Key Players Chordoma Disease Therapeutics Product Solution and Service
3.7 Date of Enter into Chordoma Disease Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chordoma Disease Therapeutics Breakdown Data by Type (2015-2026)
4.1 Global Chordoma Disease Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Chordoma Disease Therapeutics Forecasted Market Size by Type (2021-2026)
5 Chordoma Disease Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Chordoma Disease Therapeutics Historic Market Size by Application (2015-2020)
5.2 Global Chordoma Disease Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Chordoma Disease Therapeutics Market Size (2015-2026)
6.2 North America Chordoma Disease Therapeutics Market Size by Type (2015-2020)
6.3 North America Chordoma Disease Therapeutics Market Size by Application (2015-2020)
6.4 North America Chordoma Disease Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Chordoma Disease Therapeutics Market Size (2015-2026)
7.2 Europe Chordoma Disease Therapeutics Market Size by Type (2015-2020)
7.3 Europe Chordoma Disease Therapeutics Market Size by Application (2015-2020)
7.4 Europe Chordoma Disease Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Chordoma Disease Therapeutics Market Size (2015-2026)
8.2 China Chordoma Disease Therapeutics Market Size by Type (2015-2020)
8.3 China Chordoma Disease Therapeutics Market Size by Application (2015-2020)
8.4 China Chordoma Disease Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Chordoma Disease Therapeutics Market Size (2015-2026)
9.2 Japan Chordoma Disease Therapeutics Market Size by Type (2015-2020)
9.3 Japan Chordoma Disease Therapeutics Market Size by Application (2015-2020)
9.4 Japan Chordoma Disease Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Chordoma Disease Therapeutics Market Size (2015-2026)
10.2 Southeast Asia Chordoma Disease Therapeutics Market Size by Type (2015-2020)
10.3 Southeast Asia Chordoma Disease Therapeutics Market Size by Application (2015-2020)
10.4 Southeast Asia Chordoma Disease Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Chordoma Disease Therapeutics Introduction
11.1.4 GlaxoSmithKline Revenue in Chordoma Disease Therapeutics Business (2015-2020))
11.1.5 GlaxoSmithKline Recent Development
11.2 Bavarian Nordic
11.2.1 Bavarian Nordic Company Details
11.2.2 Bavarian Nordic Business Overview
11.2.3 Bavarian Nordic Chordoma Disease Therapeutics Introduction
11.2.4 Bavarian Nordic Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.2.5 Bavarian Nordic Recent Development
11.3 Boehringer Ingelheim International
11.3.1 Boehringer Ingelheim International Company Details
11.3.2 Boehringer Ingelheim International Business Overview
11.3.3 Boehringer Ingelheim International Chordoma Disease Therapeutics Introduction
11.3.4 Boehringer Ingelheim International Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.3.5 Boehringer Ingelheim International Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Chordoma Disease Therapeutics Introduction
11.4.4 Pfizer Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.4.5 Pfizer Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Chordoma Disease Therapeutics Introduction
11.5.4 Merck Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.5.5 Merck Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Chordoma Disease Therapeutics Introduction
11.6.4 Sanofi Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.6.5 Sanofi Recent Development
11.7 Astellas Pharma
11.7.1 Astellas Pharma Company Details
11.7.2 Astellas Pharma Business Overview
11.7.3 Astellas Pharma Chordoma Disease Therapeutics Introduction
11.7.4 Astellas Pharma Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.7.5 Astellas Pharma Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Chordoma Disease Therapeutics Introduction
11.8.4 AstraZeneca Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.8.5 AstraZeneca Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Chordoma Disease Therapeutics Introduction
11.9.4 Amgen Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.9.5 Amgen Recent Development
11.10 Bristol-Myers Squibb and Company
11.10.1 Bristol-Myers Squibb and Company Company Details
11.10.2 Bristol-Myers Squibb and Company Business Overview
11.10.3 Bristol-Myers Squibb and Company Chordoma Disease Therapeutics Introduction
11.10.4 Bristol-Myers Squibb and Company Revenue in Chordoma Disease Therapeutics Business (2015-2020)
11.10.5 Bristol-Myers Squibb and Company Recent Development
11.11 Novartis
10.11.1 Novartis Company Details
10.11.2 Novartis Business Overview
10.11.3 Novartis Chordoma Disease Therapeutics Introduction
10.11.4 Novartis Revenue in Chordoma Disease Therapeutics Business (2015-2020)
10.11.5 Novartis Recent Development
11.12 Bayer
10.12.1 Bayer Company Details
10.12.2 Bayer Business Overview
10.12.3 Bayer Chordoma Disease Therapeutics Introduction
10.12.4 Bayer Revenue in Chordoma Disease Therapeutics Business (2015-2020)
10.12.5 Bayer Recent Development
11.13 Dr. Reddy’s Laboratories
10.13.1 Dr. Reddy’s Laboratories Company Details
10.13.2 Dr. Reddy’s Laboratories Business Overview
10.13.3 Dr. Reddy’s Laboratories Chordoma Disease Therapeutics Introduction
10.13.4 Dr. Reddy’s Laboratories Revenue in Chordoma Disease Therapeutics Business (2015-2020)
10.13.5 Dr. Reddy’s Laboratories Recent Development
11.14 Mylan
10.14.1 Mylan Company Details
10.14.2 Mylan Business Overview
10.14.3 Mylan Chordoma Disease Therapeutics Introduction
10.14.4 Mylan Revenue in Chordoma Disease Therapeutics Business (2015-2020)
10.14.5 Mylan Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Chordoma Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Antimetabolites
Table 4. Key Players of Anthracycline
Table 5. Key Players of VEGFR Inhibitor
Table 6. Key Players of EGFR Inhibitor
Table 7. Key Players of Others
Table 8. Global Chordoma Disease Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Chordoma Disease Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Chordoma Disease Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Chordoma Disease Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Chordoma Disease Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Chordoma Disease Therapeutics Market Share by Regions (2021-2026)
Table 14. Chordoma Disease Therapeutics Market Market Trends
Table 15. Chordoma Disease Therapeutics Market Drivers
Table 16. Chordoma Disease Therapeutics Market Challenges
Table 17. Chordoma Disease Therapeutics Market Restraints
Table 18. Global Chordoma Disease Therapeutics Revenue by Players (2015-2020) (US$ Million)
Table 19. Global Chordoma Disease Therapeutics Market Share by Players (2015-2020)
Table 20. Global Top Chordoma Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chordoma Disease Therapeutics as of 2019)
Table 21. Global Chordoma Disease Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Chordoma Disease Therapeutics Product Solution and Service
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Chordoma Disease Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 26. Global Chordoma Disease Therapeutics Market Size Share by Type (2015-2020)
Table 27. Global Chordoma Disease Therapeutics Revenue Market Share by Type (2021-2026)
Table 28. Global Chordoma Disease Therapeutics Market Size Share by Application (2015-2020)
Table 29. Global Chordoma Disease Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 30. Global Chordoma Disease Therapeutics Market Size Share by Application (2021-2026)
Table 31. North America Chordoma Disease Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 32. North America Chordoma Disease Therapeutics Market Share by Type (2015-2020)
Table 33. North America Chordoma Disease Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 34. North America Chordoma Disease Therapeutics Market Share by Application (2015-2020)
Table 35. North America Chordoma Disease Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 36. North America Chordoma Disease Therapeutics Market Share by Country (2015-2020)
Table 37. Europe Chordoma Disease Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 38. Europe Chordoma Disease Therapeutics Market Share by Type (2015-2020)
Table 39. Europe Chordoma Disease Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 40. Europe Chordoma Disease Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Chordoma Disease Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 42. Europe Chordoma Disease Therapeutics Market Share by Country (2015-2020)
Table 43. China Chordoma Disease Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 44. China Chordoma Disease Therapeutics Market Share by Type (2015-2020)
Table 45. China Chordoma Disease Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 46. China Chordoma Disease Therapeutics Market Share by Application (2015-2020)
Table 47. China Chordoma Disease Therapeutics Market Size by Region (US$ Million) (2015-2020)
Table 48. China Chordoma Disease Therapeutics Market Share by Region (2015-2020)
Table 49. Japan Chordoma Disease Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 50. Japan Chordoma Disease Therapeutics Market Share by Type (2015-2020)
Table 51. Japan Chordoma Disease Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 52. Japan Chordoma Disease Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Chordoma Disease Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 54. Japan Chordoma Disease Therapeutics Market Share by Country (2015-2020)
Table 55. Southeast Asia Chordoma Disease Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 56. Southeast Asia Chordoma Disease Therapeutics Market Share by Type (2015-2020)
Table 57. Southeast Asia Chordoma Disease Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 58. Southeast Asia Chordoma Disease Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Chordoma Disease Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 60. Southeast Asia Chordoma Disease Therapeutics Market Share by Country (2015-2020)
Table 61. GlaxoSmithKline Company Details
Table 62. GlaxoSmithKline Business Overview
Table 63. GlaxoSmithKline Product
Table 64. GlaxoSmithKline Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 65. GlaxoSmithKline Recent Development
Table 66. Bavarian Nordic Company Details
Table 67. Bavarian Nordic Business Overview
Table 68. Bavarian Nordic Product
Table 69. Bavarian Nordic Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 70. Bavarian Nordic Recent Development
Table 71. Boehringer Ingelheim International Company Details
Table 72. Boehringer Ingelheim International Business Overview
Table 73. Boehringer Ingelheim International Product
Table 74. Boehringer Ingelheim International Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 75. Boehringer Ingelheim International Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Product
Table 79. Pfizer Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Merck Company Details
Table 82. Merck Business Overview
Table 83. Merck Product
Table 84. Merck Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 85. Merck Recent Development
Table 86. Sanofi Company Details
Table 87. Sanofi Business Overview
Table 88. Sanofi Product
Table 89. Sanofi Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 90. Sanofi Recent Development
Table 91. Astellas Pharma Company Details
Table 92. Astellas Pharma Business Overview
Table 93. Astellas Pharma Product
Table 94. Astellas Pharma Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 95. Astellas Pharma Recent Development
Table 96. AstraZeneca Business Overview
Table 97. AstraZeneca Product
Table 98. AstraZeneca Company Details
Table 99. AstraZeneca Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 100. AstraZeneca Recent Development
Table 101. Amgen Company Details
Table 102. Amgen Business Overview
Table 103. Amgen Product
Table 104. Amgen Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 105. Amgen Recent Development
Table 106. Bristol-Myers Squibb and Company Company Details
Table 107. Bristol-Myers Squibb and Company Business Overview
Table 108. Bristol-Myers Squibb and Company Product
Table 109. Bristol-Myers Squibb and Company Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 110. Bristol-Myers Squibb and Company Recent Development
Table 111. Novartis Company Details
Table 112. Novartis Business Overview
Table 113. Novartis Product
Table 114. Novartis Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 115. Novartis Recent Development
Table 116. Bayer Company Details
Table 117. Bayer Business Overview
Table 118. Bayer Product
Table 119. Bayer Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 120. Bayer Recent Development
Table 121. Dr. Reddy’s Laboratories Company Details
Table 122. Dr. Reddy’s Laboratories Business Overview
Table 123. Dr. Reddy’s Laboratories Product
Table 124. Dr. Reddy’s Laboratories Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 125. Dr. Reddy’s Laboratories Recent Development
Table 126. Mylan Company Details
Table 127. Mylan Business Overview
Table 128. Mylan Product
Table 129. Mylan Revenue in Chordoma Disease Therapeutics Business (2015-2020) (US$ Million)
Table 130. Mylan Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chordoma Disease Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Antimetabolites Features
Figure 3. Anthracycline Features
Figure 4. VEGFR Inhibitor Features
Figure 5. EGFR Inhibitor Features
Figure 6. Others Features
Figure 7. Global Chordoma Disease Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Chordoma Disease Therapeutics Report Years Considered
Figure 12. Global Chordoma Disease Therapeutics Market Size (US$ Million), YoY Growth 2015-2026
Figure 13. Global Chordoma Disease Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Chordoma Disease Therapeutics Market Share by Regions (2021-2026)
Figure 15. Global Chordoma Disease Therapeutics Market Share by Players in 2019
Figure 16. Global Top Chordoma Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chordoma Disease Therapeutics as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Chordoma Disease Therapeutics Revenue in 2019
Figure 18. North America Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. United States Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Canada Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Europe Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Germany Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. France Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. U.K. Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Italy Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Russia Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Nordic Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Rest of Europe Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. Asia-Pacific Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. China Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. Japan Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. South Korea Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. Southeast Asia Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. India Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Australia Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Rest of Asia-Pacific Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Latin America Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Mexico Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Brazil Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Middle East & Africa Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Turkey Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. Saudi Arabia Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. UAE Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. Rest of Middle East & Africa Chordoma Disease Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 45. GlaxoSmithKline Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 46. Bavarian Nordic Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 47. Boehringer Ingelheim International Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 48. Pfizer Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 49. Merck Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 50. Sanofi Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 51. Astellas Pharma Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 52. AstraZeneca Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 53. Amgen Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 54. Bristol-Myers Squibb and Company Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 55. Novartis Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 56. Bayer Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 57. Dr. Reddy’s Laboratories Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 58. Mylan Revenue Growth Rate in Chordoma Disease Therapeutics Business (2015-2020)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
非アルコール性脂肪肝疾患治療薬の世界市場（～2026年） Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …- アルツハイマー病治療薬の世界市場（～2026年） Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are me…
- 胃食道逆流症（GERD）治療薬の世界市場（～2026年） Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where stomach contents come back up into the esophagus resulting in either symptoms or complications. Patent expiry of blockbuster drugs prescribed for the treatment of acid reflux disorders is majorly attrib…
- 獣医感染症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Veterinary Infectious Disease Therapeutics Market The global Veterinary Infectious Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Veterinary Infectious Disease…
- フォンウィルブランド病（VWD）治療薬の世界市場（～2026年） Von Willebrand Disease is an inherited bleeding disorder that is caused by deficiency or dysfunction of Von Willebrand Factor (VWF). VWF is a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury. This protein also binds to clotting factor VIII (FVIII) in the cir…